Pfizer's post-megamerger cost-cutting record? 51,500 jobs in 7 years
29.04.2014 / Fierce Pharma
In the calm after yesterday's Pfizer–AstraZeneca deal storm, it's time to survey the potential fallout. Pfizer's aggressive strategy for avoiding taxes, totted up by <em>The Wall Street Journal</em>, politely thumped by the <em>Financial Times</em> and skewered by In the Pipeline. Fears for the U.K. science community, articulated by any number of U.K. newspapers.